Purpose: Autograft absolute lymphocyte count (A-ALC) affects survival after autologous stem cell transplantation (ASCT) in non-Hodgkin lymphoma (NHL). AMD3100, a CXCR4 antagonist, mobilizes CD34+ stem cells in patients with NHL undergoing ASCT. We sought to study the impact of AMD3100 on A-ALC collection in patients with NHL undergoing ASCT. Patients and Methods: The primary endpoint of the study was to assess the association between AMD3100 and A-ALC collection. We compared 7 consecutive patients with NHL mobilized with AMD3100 and granulocyte colony-stimulating factor with 29 control patients with NHL mobilized with granulocyte colony-stimulating factor alone. Results: Higher median A-ALCs were observed in the AMD3100 group compared with the control group (4.16 × 109 lymphocytes/kg vs. 0.288 × 109 lymphocytes/kg; P < 0.0001). With a median follow-up of 20 months (range, 4-24 months), no relapses were reported in the AMD3100 group compared with 15 of 29 in the control group (P < 0.02). Conclusion: Our data suggest that AMD3100 affects A-ALC and clinical outcome in patients with NHL undergoing ASCT.
- Autograft absolute lymphocyte count
- Granulocyte colony-stimulating factor